Time: 2024-08-24
research_worker have found that semaglutide , the active_agent ingredient in medicine like Ozempic and Wegovy , may reduce the hazard of death and lower_berth the opportunity of development cardiovascular conditions such as stroke and heart attack in people with heart failure . A Holocene survey print in the Lancet look at data from over 4,000 corpulence or corpulent participant with heart failure who take semaglutide between October 2018 and March 2021 . The survey uncover that semaglutide was associate to a 28 % decrease in major adverse cardiovascular event and a 24 % decrease in cardiovascular disease - associate death . Additionally , the drug result in a 19 % lower_berth hazard of death from all cause , bespeak potential benefit beyond cardiovascular health.
One of the reason semaglutide may offer cardiovascular benefit is its positive impact on blood pressure , blood sugar degree , and inflammation . The drug plant to addition insulin degree , which in bend lower_berth blood sugar degree . It also hour_angle anti - inflammatory effects by suppress the release of cytokine that gun_trigger inflammation response . Semaglutide 's ability to cause Weight loss may also play a function in lowering blood pressure . high blood pressure , blood sugar , and inflammation are key hazard factor for heart disease and other cardiovascular conditions.
Wegovy , a drug approve by the FDA to dainty fleshiness , has been show to reduce the hazard of heart - associate issue by up to 44 % in corpulence or corpulent person without diabetes . A survey fund by Novo Nordisk , the maker of Wegovy , look at over 17,000 people in 41 state who were over 45 old_age old with pre - exist heart disease . Over an average of 34 calendar_month , those pickings Wegovy experience lower_berth rates of cardiac complication , decrease blood pressure degree , and greater weight loss compare to the placebo group.
Wegovy belong to a class of drug name GLP-1 Receptor Agonists , which aid addition insulin degree to lower_berth blood sugar . These drug , include semaglutide , work by deceleration down food motion through the stomach and curb appetite to promote weight loss . However , approximately 17 % of Wegovy user in the survey report side effects such as cardiac , GI , and nervous system issue , lead them to drop out of the study.
It is necessity for person see weight loss medicine to discus the potential side effects and personalize hazard with a healthcare professional before start treatment . The survey highlight the promise function of medicine like semaglutide and Wegovy in not only pull_off weight loss but also reduction the hazard of cardiovascular complication in corpulence and corpulent individuals.
Business
